Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 12/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | B3GNT2 | Q9NY97 | 3/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20987129 | 1.00 | PGR (0.60) | PGRPOLBMAOBOPRM1B3GNT2 | |
| SCHEMBL19410704 | 0.82 | OPRM1 (0.51) | PGRPOLBMAOBOPRM1B3GNT2 | |
| SCHEMBL17807767 | 0.81 | MAOB (0.68) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL2975327 | 0.81 | POLB (0.62) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL2968866 | 0.80 | PGR (0.72) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL2970468 | 0.80 | PGR (0.78) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL29464129 | 0.80 | PGR (0.78) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL30819377 | 0.79 | ALDH1A1 (0.46) | PGRPOLBOPRM1 | |
| SCHEMBL22155643 | 0.79 | PGR (0.58) | PGRPOLBMAOBB3GNT2 | |
| SCHEMBL22152166 | 0.78 | PGR (0.57) | PGRPOLBMAOBB3GNT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-113382991-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20220064146-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064146-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, MAP3K20, CSNK1G3 | PGR 1927/4885POLB 2084/4885MAOB 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.